<DOC>
	<DOCNO>NCT01939496</DOCNO>
	<brief_summary>The purpose study evaluate effect canagliflozin ( JNJ-28431754 ) blood pressure reduction , compare placebo , patient hypertension type 2 diabetes mellitus stable dos anti-hyperglycemic anti-hypertensive agent . Overall safety tolerability canagliflozin assess .</brief_summary>
	<brief_title>Evaluation Blood Pressure Reduction , Safety , Tolerability Canagliflozin Patients With Hypertension Type 2 Diabetes Mellitus Stable Doses Anti-hyperglycemic Anti-hypertensive Agents</brief_title>
	<detailed_description>This randomize ( study drug assign chance ) , double blind ( neither patient study doctor know name assign treatment ) , parallel-group , 3-arm ( patient assign 1 3 treatment group ) multicenter study determine effect canagliflozin ( 100 mg 300 mg ) blood pressure ( BP ) reduction compare placebo ( pill look like treatment real medicine ) patient hypertension type 2 diabetes mellitus ( T2DM ) . The study consist 3 phase : screening phase , double-blind treatment phase follow-up period . Approximately 153 participant randomly assign 1 3 treatment group ( 1:1:1 ratio ) double-blind treatment phase receive canagliflozin 100 mg , canagliflozin 300 mg placebo 6 week . The total duration participation study approximately 13 week .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Canagliflozin</mesh_term>
	<mesh_term>Hypoglycemic Agents</mesh_term>
	<mesh_term>Antihypertensive Agents</mesh_term>
	<criteria>patient diagnosis type 2 diabetes mellitus patient hypertension ( seat office SBP &gt; =130 mmHg &lt; 160 mmHg seat office DBP &gt; = 70 mmHg screen Week 2 patient stable dos 1 3 antihypertensive agent least 5 week screen patient stable dos 1 3 oral antihyperglycemic agent must include metformin , least 8 week screen history diabetic ketoacidosis type 1 diabetes mellitus ( T1DM ) pancreas betacell transplantation fast Cpeptide &lt; 0.70 ng/mL ( 0.23 nmol/L ) body mass index &lt; 30 kg/m2 ongoing , inadequately control thyroid disorder history cardiorenal disease require treatment immunosuppressive therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Diabetes Mellitus , Type 2</keyword>
	<keyword>Hypertension</keyword>
	<keyword>Canagliflozin</keyword>
	<keyword>JNJ 28431754</keyword>
	<keyword>Sodium-Glucose Transporter 2</keyword>
	<keyword>Blood Glucose</keyword>
	<keyword>Type 2 Diabetes Mellitus</keyword>
</DOC>